维普中文期刊产品整合服务
2591篇 您的检索式:作者名="HURST"
    题名 作者 年代 出处 被引量
1Comparative Analysis of the Determinants of China's State-owned Outward Direct Investment in OECD and Non-OECD Countries显示文摘中国向外直接的投资(ODI ) 以崭新的率正在膨胀。现在的学习扩充决定因素的理解和中国 ODI 的司机。它在中国 ODI 上考察文学,明确地集中于汉语的决定因素之间的差别并且由为时期的国有企业(SOE ) 的分析投资 20032008 投资在发展(经济合作与发展组织) 并且发展中(非经济合作与发展组织) 经济。另外,学习估计使用调查 ODI 决定因素(Dunning 的折衷的范例) 分析中国 SOE 的经验的一般框架的适当。调查结果显示 Dunning 的折衷的范例为在发达国家分析中国 SOE 投资的决定因素提供一个优秀理论框架,并且在开发国家为中国投资的分析提供一个好起点。然而, Dunning 的说明为开发国家要求精炼。这份报纸发现中国 SOE 投资的动机之间的不同差别在发展并且发展中的国家。Luke Hurst 2011China & World Economy2011,19,4:24
2Boceprevir,GC-376,and calpain inhibitors Ⅱ,Ⅻ inhibit SARS-CoV-2 viral replication by targeting the viral main protease显示文摘A new coronavirus SARS-CoV-2,also called novel coronavirus 2019(2019-nCoV),started to circulate among humans around December 2019,and it is now widespread as a global pandemic.The disease caused by SARS-CoV-2 virus is called COVID-19,which is highly contagious and has an overall mortality rate of 6.35%as of May 26,2020.There is no vaccine or antiviral available for SARS-CoV-2.In this study,we report our discovery of inhibitors targeting the SARS-CoV-2 main protease(Mpro).Using the FRET-based enzymatic assay,several inhibitors including boceprevir,GC-376,and calpain inhibitorsⅡ,andⅫwere identified to have potent activity with single-digit to submicromolar ICs0 values in the enzymatic assay.The mechanism of action of the hits was further characterized using enzyme kinetic studies,thermal shift binding assays,and native mass spectrometry.Significantly,four compounds(boceprevir,GC-376,calpain inhibitorsⅡandⅫ)inhibit SARS-CoV-2 viral replication in cell culture with EC50 values ranging from 0.49 to 3.37μM.Notably,boceprevir,calpain inhibitorsⅡandⅫrepresent novel chemotypes that are distinct from known substrate-based peptidomimetic Mpro inhibitors.A complex crystal structure of SARS-CoV-2 Mpro with GC-376,determined at 2.15(A)resolution with three protomers per asymmetric unit,revealed two unique binding configurations,shedding light on the molecular interactions and protein conformational flexibility underlying substrate and inhibitor binding by Mpro.Overall,the compounds identified herein provide promising starting points for the further development of SARS-CoV-2 therapeutics.Chunlong Ma Michael Dominic Sacco Brett Hurst Julia Alma Townsend Yanmei Hu Tommy Szeto Xiujun Zhang Bart Tarbet Michael Thomas Marty Yu Chen Jun Wang 2020Cell Research2020,30,8:13
3Handgrip strength and health outcomes: Umbrella review of systematic reviews with meta-analyses of observational studies显示文摘Purpose:The aim of the present study was to assess both the credibility and strength of evidence arising from systematic reviews with meta-analyses of observational studies on handgrip strength and health outcomes.Methods:An umbrella review of systematic reviews with meta-analyses of observational studies was conducted.We assessed meta-analyses of observational studies based on random-effect summary effect sizes and their p values,95%prediction intervals,heterogeneity,small-study effects,and excess significance.We graded the evidence from convincing(Class I)to weak(Class IV).Results:From 504 articles returned in a search of the literature,8 systematic reviews were included in our review,with a total of 11 outcomes.Overall,nine of the 11 of the outcomes reported nominally significant summary results(p<0.05),with 4 associations surviving the application of the more stringent p value(p<106).No outcome presented convincing evidence.Three associations showed Class II evidence(i.e.,highly suggestive):(1)higher handgrip values at baseline were associated with a minor reduction in mortality risk in the general population(n=34 studies;sample size=1,855,817;relative risk=0.72,95%confidence interval(95%CI):0.670.78),(2)cardiovascular death risk in mixed populations(n=15 studies;relative risk=0.84,95%CI:0.780.91),and(3)incidence of disability(n=7 studies;relative risk=0.76,95%CI:0.660.87).Conclusion:The present results show that handgrip strength is a useful indicator for general health status and specifically for early all-cause and cardiovascular mortality,as well as disability.To further inform intervention strategies,future research is now required to fully understand mechanisms linking handgrip strength scores to these health outcomes.Pinar Soysal Christopher Hurst Jacopo Demurtas Joseph Firth Reuben Howden Lin Yang Mark A.Tully Ai Koyanagi Petre Cristian Ilie Guillermo F.Lopez-Sanchez Lukas Schwingshackl Nicola Veronese Lee Smith 2021Journal of Sport and Health Science2021,10,3:5
4Spinal dural arteriovenous fistula:the pathology of venous hypertensive myelopathy显示文摘HURST R KENYON L LAVI E 1995Neurology1995,45,7:2
5Diagnosis and endovascular treatment of iliocaval compression syndrome显示文摘Hurst DR Forauer AR Bloom JR Journal of Vascular Surgery0,,:2
6Enhancement of neuromuscular recovery after nerve repair in primates 显示文摘Badala mente MA Hurst LC Paul SB 1987J Hand Surg1987,12,2:2
7Adhesion formation after intracapsular myomectomy with or without adhesion barrier显示文摘Andrea Tinelli Antonio Malvasi Marcello Guido Daniel Alberto Tsin Gernot Hudelist Brad Hurst Michael Stark Liselotte Mettler 2011Fertility and Sterility2011,,5:2
8IL-25 Induces IL-4, IL-5, and IL-13 and Th2-Associated Pathologies In Vivo显示文摘Madeline M. Fort Jeanne Cheung David Yen Joana Li Sandra M. Zurawski Sylvia Lo Satish Menon Teresa Clifford Brisdell Hunte Robin Lesley Tony Muchamuel Stephen D. Hurst Gerard Zurawski Michael W. Leach Daniel M. Gorman Donna M. Rennick 2001Immunity2001,,6:2
9生物炭在柑橘皮厌氧发酵中作用机理研究显示文摘该研究主要调查柑橘皮废料厌氧消化能力在不同类型的生物炭和不同比率下的影响。柑橘皮对厌氧消化有抑制作用。生物炭的存在有两种影响:相对于只有柑橘皮废料的培养来说,它减少了迟滞期的长度,并且使甲烷的产量更高。微生物迟滞期随着柑橘皮与生物炭比例的增加而降低,在比例为2∶1时停滞期最长,为9.4 d,在比例为1∶3时迟滞期最短,为7.5 d。生物炭和柑橘皮培养中累积的甲烷产量在163.9到186.8 mLCH4 ·g^-1VS之间变动,而只有柑橘皮培养中的甲烷产量只有165.9 mLCH4 ·g^-1VS。在检测生物炭材料时发现了推测的产甲烷菌群。D-柠檬烯吸附和微生物固定化的协同作用在生物炭的影响下会提高厌氧消化的性能。Michael O Fagbohungbe Ben M J Herbert Lois Hurst Hong Li Shams Q Usmani Kirk T Semple 张冀川(译) 2019中国沼气2019,37,5:2
10Acinetobacter baumannii : an emerging multidrug--resistant pathogen in critical care 显示文摘Montefour K Frieden J Hurst S 2008Crit Care Nurse2008,28,1:1
11Exacerbations and time spent outdoors in chronic obstructive pulmonary disease显示文摘Donaldson GC Wilkinson TMA Hurst JR 2005Am J Respir Crit Care Med2005,171,:1
12Complete genomes of two clinical Staphylococcus aureus strains:evidence for the rapid evolution of virulence and drug resistance显示文摘Holden MT Feil EJ Lindsay JA Peacock SJ Day NP Enright MC Foster TJ Moore CE Hurst L Atkin R Barron A Bason N Bentley SD Chillingworth C Chillingworth T Churcher C Clark L Corton C Cronin A Doggett J Dowd L Feltwell T Hance Z Harris B Hauser H Holroyd S Jagels K James KD Lennard N Line A Mayes R Moule S Mungall K Ormond D Quail MA Rabbinowitsch E Rutherford K Sanders M Sharp S Simmonds M Stevens K Whitehead S Barrell BG Spratt BG Parkhill J 2004Proc Natl Acad Sci USA2004,101,26:1
13, Trans-activation of PPARa and induction of PPARa target genes by perfluorooctane-based chemicals 显示文摘Shipley J M Hurst C H Tanaka S S 2004Toxicological Sciences2004,80,:1
14The reJationship of the double crush to carpal tunnel syndrome, (an analysis of 1000 cases of carpal tunnel syndrome)显示文摘Hurst LC Weissherg D Carroll RE 1985J Hand Stag(Br)1985,10,:1
15Novastan(brand of argatroban):asmall-molecule,direct thrombin inhibitor显示文摘Hursting MJ Alford KL Becker JC 1997Semin Thromb Hemost1997,23,:1
16Gatifloxacin:a new review of its use in the management of bacterial infections显示文摘Perry CM Ormrod D Hurst M 2002Drugs2002,62,1:1
17Delayed oral estradiol combined with leuprolide increases endometriosis-related pain显示文摘Hurst BS Gardner SC Tucker KE 2000JSLS2000,4,2:1
18Who are the busiest nurses显示文摘Hurst K 2009Nursing Standard2009,23,42:1
19Production of ammonia by tobacco and soybean inoculated with baeteria显示文摘Hurst C Kennedy B W Olson L 1973Phytopathololgy1973,63,:1
20A Four-Channel Time-Interleaved ADC With Digital Calibration of Interchannel Timing and Memory Errors显示文摘Law C H Hurst P J Lewis S H 2010IEEE J Solid-State Circuits2010,45,10:1
返回顶部 每页显示:
共130页 首页 上一页 第1页 下一页 末页 /130 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费